MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 100920 | Name: Vincristine sulfate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vincristine sulfate is the sulfate salt of a natural alkaloid isolated from the periwinkle plant of the oleander family with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.

Chemical Structure

Vincristine sulfate
Vincristine sulfate
CAS#2068-78-2 (sulfate)

Theoretical Analysis

MedKoo Cat#: 100920

Name: Vincristine sulfate

CAS#: 2068-78-2 (sulfate)

Chemical Formula: C46H56N4O10

Exact Mass: 0.0000

Molecular Weight: 824.96

Elemental Analysis: C, 66.97; H, 6.84; N, 6.79; O, 19.39

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
1g USD 2,950.00 Ready to Ship
5g USD 8,950.00 Ready to Ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
57-22-7 (free base) 2068-78-2 (sulfate)
Synonym
leurocristine sulfate, Vincasar PFS, Oncovin, VCR
IUPAC/Chemical Name
(3aR,3a1R,4R,5S,5aR,10bR)-methyl 4-acetoxy-3a-ethyl-9-((3S,5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-2,4,5,6,7,8,9,10-octahydro-1H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate.
InChi Key
AQTQHPDCURKLKT-JKDPCDLQSA-N
InChi Code
InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+;/m1./s1
SMILES Code
O=C([C@]1(O)[C@]2([H])N(C=O)C3=C(C=C([C@@]4(C(OC)=O)C[C@@]5([H])C[C@@](O)(CC)C[N@](C5)CCC6=C4NC7=C6C=CC=C7)C(OC)=C3)[C@]2(CCN8CC=C9)[C@]8([H])[C@]9(CC)[C@H]1OC(C)=O)OC.O=S(O)(O)=O
Appearance
White to off-white, odorless amorphous or crystalline powder
Purity
>99% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, water, slightly soluble in ethanol.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle and binds to microtubules with a Ki of 85 nM.
In vitro activity:
The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia. In order to decrease toxicity and chemoresistance of vincristine, the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells were investigated. Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM. This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation. These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway. Reference: J Hematol Oncol. 2015 Jul 10;8:82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504084/
In vivo activity:
Whisker hair follicles are tactile organs in non-primate mammals which are functionally equivalent to human fingertips. Mouse whisker hair follicles were used as a model system and the pressure-clamped single-fiber recording technique was applied in order to explore how vincristine treatment affect mechanoreceptors in whisker hair follicles. In vivo treatment of mice with vincristine impaired whisker tactile behavioral responses. The pressure-clamped single-fiber recordings made from whisker hair follicle afferent nerves showed that mechanical stimulations evoked three types of mechanical responses, rapidly adapting response (RA), slowly adapting type 1 response (SA1) and slowly adapting type 2 response (SA2). Vincristine treatment significantly reduced SA1 responses but did not significantly affect RA and SA2 responses. These findings suggest that SA1 mechanoreceptors were selectively impaired by vincristine leading to the impairment of in vivo whisker tactile behavioral responses. Reference: Neurosci Lett. 2020 Nov 1;738:135355. https://www.sciencedirect.com/science/article/abs/pii/S030439402030625X?via%3Dihub
Solvent mg/mL mM
Solubility
DMSO 62.5 75.76
Water 83.3 101.01
DMF 3.0 3.64
PBS (pH 7.2) 2.0 2.42
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 824.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015 Jul 10;8:82. doi: 10.1186/s13045-015-0176-7. PMID: 26156322; PMCID: PMC4504084. 2. Sonekatsu M, Kanno S, Yamada H, Gu JG. Selective impairment of slowly adapting type 1 mechanoreceptors in mice following vincristine treatment. Neurosci Lett. 2020 Nov 1;738:135355. doi: 10.1016/j.neulet.2020.135355. Epub 2020 Sep 6. PMID: 32905836; PMCID: PMC7584766.
In vitro protocol:
1. Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, Teng CM. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015 Jul 10;8:82. doi: 10.1186/s13045-015-0176-7. PMID: 26156322; PMCID: PMC4504084.
In vivo protocol:
1. Sonekatsu M, Kanno S, Yamada H, Gu JG. Selective impairment of slowly adapting type 1 mechanoreceptors in mice following vincristine treatment. Neurosci Lett. 2020 Nov 1;738:135355. doi: 10.1016/j.neulet.2020.135355. Epub 2020 Sep 6. PMID: 32905836; PMCID: PMC7584766.
1: Rameika N, Tsiara I, Zhang X, Haberek W, Rendo V, Kundu S, Correia MSP, Stoimenov I, Globisch D, Sjöblom T. NAT2 activity increases cytotoxicity of anthracycline antibiotics and HDAC inhibitors. Biochim Biophys Acta Mol Basis Dis. 2025 Mar 12;1871(5):167755. doi: 10.1016/j.bbadis.2025.167755. Epub ahead of print. PMID: 40081304. 2: Bennebroek CAM, van Zwol J, Montauban van Swijndregt MC, Porro GL, Oostenbrink R, Dittrich ATM, Pott JW, Meijer L, Janssen EJM, Klinkenberg S, Bauer NJ, Notting IC, van Genderen MM, Tanck MW, de Graaf P, Saeed P, Schouten- van Meeteren AYN. A Retrospective, Nationwide, Multicenter Study on Diagnosis and Treatment Outcome of Pediatric Optic Pathway/Hypothalamic Gliomas Including Analysis of Risk Factors for Progression After Systemic Anticancer Therapy. Cancers (Basel). 2025 Feb 20;17(5):716. doi: 10.3390/cancers17050716. PMID: 40075564; PMCID: PMC11898773. 3: de Mello RS, Bento CA, de Oliveira Faria R, Arnaud-Sampaio VF, Ulrich H, Miyagi MYS, de Araujo GLB, Lameu C. Effects of nanoflubendazole and purinergic signaling modulation in overcoming neuroblastoma chemoresistance. Purinergic Signal. 2025 Mar 13. doi: 10.1007/s11302-025-10078-7. Epub ahead of print. PMID: 40075009. 4: Valentin T, Winter S, Martin V, Csanyi M, Marec Berard P, Laurence V, Gaspar N. Primary cutaneous/subcutaneous Ewings sarcoma. Bull Cancer. 2025 Mar 11:S0007-4551(25)00079-7. doi: 10.1016/j.bulcan.2023.10.011. Epub ahead of print. PMID: 40074591. 5: Winter S, Valentin T, Ducassou A, Helfre S, Berlanga P, Lemelle L, Marie- Cardine A, Rouquette PB, Laurence V. Recommandations françaises de prise en charge des tumeurs d’Ewing métastatiques extra-pulmonaires (GroupOs) [Extra- pulmonary metastatic Ewing sarcoma: The French GroupOs diagnostic and therapeutic recommendations]. Bull Cancer. 2025 Mar 11:S0007-4551(25)00081-5. French. doi: 10.1016/j.bulcan.2024.01.014. Epub ahead of print. PMID: 40074589. 6: Li X, Yang H, Qian M, Liu H, Zuo S, Liu JC, Ge WH, Zhou L. Intracellular metabotropic glutamate receptor 5 in spinal dorsal horn neurons contributes to pain in a mouse model of vincristine-induced neuropathic pain. Neurosci Lett. 2025 Mar 10:138193. doi: 10.1016/j.neulet.2025.138193. Epub ahead of print. PMID: 40074023. 7: Şahin Ö, Tanriverdi H, Seber T, Taşdemir A. Primary cardiac lymphoma presenting with wide QRS tachycardia: a case report. Eur Heart J Case Rep. 2025 Mar 11;9(3):ytaf065. doi: 10.1093/ehjcr/ytaf065. PMID: 40070801; PMCID: PMC11894249. 8: Place AE, Karol SE, Forlenza CJ, Cooper TM, Fraser C, Cario G, O'Brien MM, Gerber NU, Bourquin JP, Reinhardt D, Rubnitz JE, Opferman JT, Sunkersett G, Onishi M, Dunshee DR, Chen X, Unnebrink K, Vishwamitra D, Dunbar F, Badawi M, Ross JA, Loh ML. Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2025 Mar 10:e31630. doi: 10.1002/pbc.31630. Epub ahead of print. PMID: 40062648. 9: Malpica L, Idrobo H, Pavlovsky A, Miranda ECM, Castro D, Beltran B, Enriquez DJ, Vasquez JF, Roche C, Valvert F, Villela L, Fischer T, Pereira J, Baptista RLR, Duffles G, Brasil SAB, Oliver C, Tavarez JV, Warley F, Fiad L, Korin L, Pereyra PH, Roa M, Torres MA, Mahuad CV, Quiroz AR, Gazitua R, Federico M, Valcarcel B, Chiattone C. Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study. Lancet Haematol. 2025 Mar 5:S2352-3026(25)00011-0. doi: 10.1016/S2352-3026(25)00011-0. Epub ahead of print. PMID: 40056928. 10: Kaur A, Kaur R, Bhardwaj U, Sharma P. Optimisation and utilization of deep eutectic solvents for the green extraction of anticancer alkaloids from Catharanthus roseus. Nat Prod Res. 2025 Mar 8:1-9. doi: 10.1080/14786419.2025.2476199. Epub ahead of print. PMID: 40056015. 11: Xie W, Cao L, Yu J, Tian A, Wang J, Lin R. 18F-FDG PET/CT metabolic parameter changes to assess vascular inflammatory response in patients with diffuse large B-cell lymphoma. BMC Med Imaging. 2025 Mar 7;25(1):81. doi: 10.1186/s12880-025-01617-0. PMID: 40055673; PMCID: PMC11889901. 12: Mitsuyuki S, Okazaki S, Mukai S, Matsuura A, Yasuhara Y, Tanaka A, Oshima K, Hatanaka K. Central nervous system relapse of primary cutaneous anaplastic large cell lymphoma: A case report. EJHaem. 2025 Mar 6;6(2):e1082. doi: 10.1002/jha2.1082. PMID: 40052018; PMCID: PMC11883415. 13: Lin TB, Kuo CY, Chang FC, Lin SC, Chen YW, Liang ML, Lee YY. Carboplatin and vinblastine monthly in the optic pathway and hypothalamic gliomas: A retrospective analysis in a single institute. Neurooncol Adv. 2025 Jan 29;7(1):vdaf020. doi: 10.1093/noajnl/vdaf020. PMID: 40051663; PMCID: PMC11883347. 14: Gao Y, Tang Y, Wei C, Yu Y, Xie J, Li Y, Wei S, Xing J, Pan X. Modeling substrate efflux in human P-glycoprotein at the atomic level. J Biomol Struct Dyn. 2025 Mar 7:1-13. doi: 10.1080/07391102.2025.2474048. Epub ahead of print. PMID: 40051309. 15: Kim MJ, Cho J, Kim WS, Kim SJ, Yoon SE. Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma. Leuk Lymphoma. 2025 Mar 3:1-12. doi: 10.1080/10428194.2025.2471500. Epub ahead of print. PMID: 40029982. 16: Arega G, Adam H, Girma A, Diida G, Beresa E, Adane L, Negussie MA, Abrar FN, Asefa M. Pediatric T-Cell/Histiocyte-Rich Large B-Cell Lymphoma (THRLBC) in an 8-Year-Old Male Child: A Case Report. Case Rep Oncol Med. 2025 Feb 22;2025:8869045. doi: 10.1155/crom/8869045. PMID: 40026533; PMCID: PMC11871974. 17: Chen S, Chen H, Song S, Wang MB. Sinonasal Plasmablastic Lymphoma: A Systematic Review. J Neurol Surg Rep. 2024 Nov 13;85(4):e167-e177. doi: 10.1055/a-2444-3438. PMID: 40026453; PMCID: PMC11869385. 18: Okano Y, Oyake T, Kitamura S, Asano K, Sato T, Maeta T, Miyajima S, Otsu A, Nishiya M, Sasaki R, Kowata S, Ishida Y, Ito S. Prognostic predictors of newly diagnosed Diffuse large B-cell lymphoma treated with R-THP-COP regimen. J Clin Exp Hematop. 2025 Feb 28. doi: 10.3960/jslrt.24073. Epub ahead of print. PMID: 40024743. 19: Lindström L, Zhou J, Villoutreix BO, Malycheva D, Otrocka M, Gustavsson AL, Lundbäck T, Bliman D, Shameem MA, Straw M, Riesbeck K, Olsson R, Alvarado- Kristensson M. Targeting TUBG1 in RB1-negative tumors. FASEB J. 2025 Mar 15;39(5):e70431. doi: 10.1096/fj.202403180RR. PMID: 40019206; PMCID: PMC11869804. 20: Almatar ERE, Alsharidah S, Bourusly M, Ahmed RL, Alabdulhadi MA. Guillain- Barre Syndrome with Acute Lymphoblastic Leukemia: Case Report. Int Med Case Rep J. 2024 Dec 10;17:1013-1018. doi: 10.2147/IMCRJ.S496062. PMID: 40017997; PMCID: PMC11864905.